James M. Mock Sells 1,321 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) CFO James M. Mock sold 1,321 shares of the firm's stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company's stock, valued at $682,754. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Moderna Price Performance

Moderna stock traded down $0.77 during mid-day trading on Thursday, reaching $77.59. 3,307,062 shares of the company were exchanged, compared to its average volume of 4,086,561. The company has a fifty day simple moving average of $106.87 and a 200-day simple moving average of $113.12. The firm has a market cap of $29.74 billion, a PE ratio of -4.96 and a beta of 1.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business's revenue for the quarter was down 29.9% on a year-over-year basis. During the same period in the prior year, the company posted ($3.62) earnings per share. As a group, equities research analysts expect that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on MRNA shares. Oppenheimer upped their price objective on Moderna from $163.00 to $179.00 and gave the company an "outperform" rating in a research note on Wednesday, June 12th. Barclays cut their price target on Moderna from $168.00 to $155.00 and set an "overweight" rating for the company in a report on Friday, August 2nd. Royal Bank of Canada downgraded shares of Moderna from an "outperform" rating to a "sector perform" rating and decreased their price objective for the company from $125.00 to $90.00 in a report on Monday, August 5th. UBS Group raised their target price on shares of Moderna from $143.00 to $151.00 and gave the stock a "buy" rating in a research note on Tuesday, May 7th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a research note on Thursday, August 1st. Ten analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $123.79.

Institutional Investors Weigh In On Moderna

A number of large investors have recently modified their holdings of MRNA. Vanguard Group Inc. grew its position in Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company's stock valued at $4,159,769,000 after acquiring an additional 5,129,800 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Moderna by 28.8% during the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company's stock valued at $718,584,000 after purchasing an additional 1,614,460 shares during the last quarter. Capital World Investors lifted its stake in Moderna by 0.5% in the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company's stock valued at $388,743,000 after purchasing an additional 18,728 shares during the last quarter. Norges Bank acquired a new stake in Moderna in the fourth quarter valued at approximately $347,565,000. Finally, Mawer Investment Management Ltd. grew its stake in shares of Moderna by 6.7% during the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company's stock worth $204,230,000 after buying an additional 120,621 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.